Top Markets
#1 GEKKO GEKKO +52.86%
#2 TENDIES TENDIES +48.87%
#3 Helium Helium +46.85%
#4 Pons Pons +41.91%
#5 ADO Protocol ADO Protocol +39.18%
#6 Prom Prom +33.01%
#7 Collector Crypt Collector Crypt +20.14%
#8 Nillion Nillion +19.44%
#9 龙虾 (Lobster) 龙虾 (Lobster) +18.52%
#10 o1.exchange o1.exchange +18.40%
Coin of the day
GEKKO GEKKO
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
CARsgen Therapeutics Holdings Limited CARsgen Therapeutics Holdings Limited

CARsgen Therapeutics Holdings Limited

2171
Classifica tra le azioni #9600
CARsgen Therapeutics Holdings Limited, a biopharmaceutical firm founded in... CARsgen Therapeutics Holdings Limited, a biopharmaceutical firm founded in Shanghai, China, in 2014, focuses on the discovery, development, and commercialization of advanced chimeric antigen receptor T (CAR-T) cell therapies. The company's efforts are directed toward treating various hematological malignancies and solid tumors across China and the United States. Its robust pipeline includes several key candidates: CT053, an autologous CAR-T product, is currently in a pivotal Phase II trial in China for relapsed/refractory multiple myeloma. Additionally, CT041, another autologous CAR-T, is undergoing Phase Ib/II clinical trials for advanced gastric/gastroesophageal junction and pancreatic cancers in China, and Phase Ib trials for comparable indications in the U.S. CARsgen is also advancing CT011, an autologous CAR-T candidate, through Phase I for patients with Glypican-3 positive advanced hepatocellular carcinoma, and CT032, an autologous CAR-T, in Phase I/II for B cell Non-Hodgkin's lymphoma in China. Furthermore, its pipeline features AB011, a humanized monoclonal antibody in Phase I for CLDN18.2 positive solid tumors in China, as well as CT017, an autologous Glypican-3-targeted CAR-T for hepatocellular carcinoma, and other promising therapies for solid tumors.
Prezzo delle azioni
$1.72
Ultima sincronizzazione: 2026-08-28
Capitalizzazione di mercato
$981.92M
Variazione (1 giorno)
-1.68%
Variazione (1 anno)
-41.83%
Paese
CN
Scambia CARsgen Therapeutics Holdings Limited (2171)

Categoria

Healthcare
Utile per CARsgen Therapeutics Holdings Limited (2171)
Utile nel 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di CARsgen Therapeutics Holdings Limited, gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, uguale a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di CARsgen Therapeutics Holdings Limited dal 2026 al 2026
Utile alla fine di ogni anno
Anno Utile Cambia
Non abbastanza dati per le date fornite.
Utile per aziende simili o concorrenti
Azienda Utile Differenza negli utili Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH